Investment Portfolio

We have the expertise. We have the track record. We put Ontario First. FACIT actively manages its diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development. Our active portfolio consists of both early-stage assets and more than 30 companies advancing oncology therapeutics, medical technologies, diagnostics and informatics/AI. Our portfolio has raised more than $1B from global investors in follow-on financing.

Investment Philosophy

FACIT strategically invests in oncology breakthroughs and companies arising from Ontario’s outstanding innovation ecosystem. By fostering a culture of entrepreneurship and commitment to the value of commercialization, we support inventors and researchers in capitalizing on their cancer related innovations.

Why invest with FACIT

Our partners gain access to outstanding science and oncology innovations in a variety of areas such as new technology, therapeutics, imaging and diagnostics. Through our expertise in identifying and commercializing the most promising assets, we help investors reduce the risk of their early-stage involvement.

SEARCH FILTERS:

Innovation Type
Cancer Type
Current Funding Stage
FACIT Fund


Sort by:

Air Microfluidic Systems Inc.

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
Air microfluidics-enabled active compression sleeve for treating breast cancer-related lymphedema

Western University (Tenomix)

Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Prospects
A bench-top ultrasound-based device that can automate the detection of lymph nodes in resected colorectal cancer tissue

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Prostate
Funding Stage:
Proof of Concept
Fund:
Prospects
At-home prostate cancer screening kit

Bridge7 Oncology

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes, Prospects
Scaling clinical expertise with AI to automate and improve the delivery of cancer care.

Replica Analytics

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Modeling software to create synthetic data based on real clinical datasets

Multimagnetics Inc.

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Hand-held photoacoustic device to detect tumour margins and residual disease in the surgical cavity during breast-conserving surgery

University of Toronto

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Development of small-molecule inhibitors of mitochondrial RNA polymerase (POLRMT) as an anticancer strategy

Radiant Biotherapeutics

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Multivalent, multi-specific antibody nanoparticle platform for therapeutic development

Cellular Analytics

Innovation Type:
Diagnostics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose
Microfluidic platform and lung cancer biomarker chip used to match patients with the most effective therapy for improved treatment outcomes.

Xpan Inc

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Falcons’ Fortunes, Prospects
Developing A Less Invasive Access Port To Maximize The Potential Of Laparoscopic Surgical Oncology

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
WD Repeat Platform

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy

University of Toronto (Perturba)

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time

Polumiros

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Falcons’ Fortunes
ReFilx, a Polymeric Soft Tissue Filler for the Permanent Restoration of Breast Tissue Defects following Lumpectomy

Talon Pharma

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Prospects
Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation

CCRM (Notch Therapeutics)

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
A Method for Generating Progenitor T-Cells from Stem and/or Progenitor Cells for Universal CAR-T Therapy

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
ADC-Linker Platform

Nanology

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
A novel nano-theranostic platform technology with capabilities to simultaneously enhance MRI contrast signal in the tumor and enhance the radiation therapy efficacy

16-Bit

Innovation Type:
Informatics & AI
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Prospects
Automatic Analysis of Screening Mammograms for Breast Cancer

DNAStack

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
Development of a Cloud Platform for Genomics Data Management, Analysis and Sharing

Dalriada Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Seed
Fund:
Prospects
Development of DT-1 Class of Small Molecules for the Treatment of Leukemia

KA Imaging

Innovation Type:
Medical Technologies
Cancer Type:
Other
Funding Stage:
Seed
Fund:
Prospects
Multi-spectral Digital X-ray Imager

Radialis Medical

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Prospects
Positron Emission Mammography (PEM) Imaging System to Detect Pre-Invasive Breast Cancers

University of Ottawa

Innovation Type:
Therapeutics
Cancer Type:
pancreas
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer

OICR

Innovation Type:
Diagnostics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Molecular Profiling for Anthracycline Sensitivity in Patients receiving Chemo for Breast Cancer

Realist Pharma

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Prospects
Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.

Talon Pharma

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Prospects
Cell Permeable KV1.3 Antagonists: Novel Targeting of Apoptosis in Cancer Treatment

Queens University

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Prospects
Development of Novel CYP26 Inhibitors for the treatment of AML

Fusion Pharmaceuticals Inc.

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Next-generation radiopharmaceuticals for precision medicine (antibody Conjugate for Lung Cancer), prividing a safer approach to targeted radiotherapy by helping the drug clear from normal, healthy tissues and reducing toxicity.

Novera Therapeutics Inc.

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Seed
Fund:
Compass Rose
Development of BCL6 Inhibitors for Treatment of Hematological Cancers

FocusOnCare

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
ChemoTracker App Development

Capnostics

Innovation Type:
Medical Technologies
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Prospects
Resurrection of the FDA File and Manufaturing of CellMate Product for Esophageal Cell Sampling

Sunnybrook Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
External Clinical Validation Study of a Quantitative Ultrasound Spectral Analysis Platform For Monitoring Tumor Response In Women Receiving Neoadjuvent Chemotherapy for Locally Advanced Breast Cancer

OICR

Innovation Type:
Diagnostics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Ring Study to Evaluate the PRedicTive brEast Cancer Test (PRoTECT)

Sunnybrook Research Institute

Innovation Type:
Therapeutics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and GSK AS15 adjuvant

Ziliomics

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose, Prospects
Development of Heliotrope Bioinformatics Software Platform

Sunnybrook Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
Ultra-Low Dose Microbubbles for Cancer

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Fully synthetic, self-adjuvanting vaccines incorporating tumor-associated antigenic epitopes for cancer immunotherapy

Turnstone Biologics Inc.

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Transforming patient care with a new class of targeted viral immunotherapies to fight cancer (Marabavirus-based oncolytic viral vector)

Fluorinov Pharma (Trillium)

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
FV162 Oral Proteasome Inhibitor

OICR (Cellax)

Innovation Type:
Therapeutics
Cancer Type:
pancreas
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Cellax Nanoparticles for Enhanced Cancer Treatment

XLV Diagnostics

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Series A,B,C
Fund:
Compass Rose
X-ray light valve (XLV) for low-cost digital mammography

Privacy Analytics

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Software unlocking the vast potential of medical data without compromising individual privacy or causing unacceptable distortion of the data

Harmonic Medical

Innovation Type:
Medical Technologies
Cancer Type:
Liver
Funding Stage:
Series A,B,C
Fund:
Compass Rose
A system using ultrasound to both detect and treat tumours in bone and liver for the relief of pain without surgery and without expensive imaging equipment.

McMaster University

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of Radiolabeled Insulin Probe

Triphase Accelerator Corporation

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Formation of an Accelerator enterprise designed to take drug candidates from IND through to clinical proof-of-concept. Later decided to accept pre-IND assets as well.

Univeristy of Toronto (Kapplex)

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
A Digital Microfluidics Platform for High-Throughput Apoptosis Screening

Xagenic

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Validation of the GenEplex platform for clinically accepted leukemia biomarkers

DLVR Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel nanoparticle delivery technology.

University of Toronto (Receptor-OncoTek)

Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Preclinical development of PoLi-PTX, Intraperitoneal Ovarian Cancer Therapy

DVS Sciences (Fluidigm)

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Flow cytometer-mass spectrometer for multi-parametric cell and bead analysis

UHN (TorCell Therapeutics)

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel T-cell Immunotherapy (autologous cellular therapy)

UHN

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of novel chemical proteosome inhibitors

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Glypican-3: a novel marker for the early diagnosis of hepatocellular carcinoma

UHN

Innovation Type:
Medical Technologies
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel Radio Frequency Ablation Technology for Treatment of Solid Tumours

ArcticDx

Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of a colon cancer risk prediction diagnostic tool

Robarts Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Prostate
Funding Stage:
Proof of Concept
Fund:
Compass Rose
3D ultrasound-guided intraoperative and dynamic minimally invasive trans-perineal prostate therapy and biopsy platform


In June 2020, FACIT was nationally recognized by industry peers with a Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA). The award acknowledges FACIT’s strategic commercialization investments that have positioned our portfolio companies to deliver meaningful impacts on Ontario’s life sciences industry. FACIT is the first and only Ontario life science commercialization organization to achieve this recognition.


    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.